Moreover, our data show that combined targeting of the PI3-kinase/mTOR pathway and BCL-2 family members using BEZ235 and obatoclax leads to synergistic growth-inhibitory effects in ALL cells. Here, BCL2 is linked to acute lymphoblastic leukemia.